The abstract is read at the publisher; the summary is JClub's.
Next-generation CDK inhibitors for HR+/HER2- breast cancer aim to improve selectivity and durability beyond current CDK4/6 regimens, addressing toxicity, cytostatic limits, and resistance.
- Why it matters: CDK4/6 inhibitors plus endocrine therapy changed care, but hematologic toxicity, incomplete largely cytostatic responses, and near-universal resistance leave major gaps.
- What they did: This Review surveys emerging CDK4-selective inhibitors, CDK2-directed approaches, and multi-CDK strategies, linking their design to resistance mechanisms and cell-cycle rewiring.
- The result: Refining target specificity and countering resistance-associated cell-cycle changes may reduce toxicity, enhance treatment durability, and support better combination and sequencing across advanced and early-stage settings.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.